Janssen Israel and Sheba ARC

Janssen Israel and Sheba ARC, we want to be.an innovation hub set up by Sheba Medical Center to develop and promote digital health Solutions

“ Our strategy, as is Sheba's is to lead by innovation. We're a very patient-centric company with the goal to 'go beyond the pill' - adding value to our customers and maximizing treatment results.”

As the pharmaceutical division of Johnson & Johnson, Janssen focuses on developing innovative molecules for patients in different therapeutic areas, to serve unmet medical needs. This aligns well with Sheba's position as one of the world's most digitally advanced hospitals.

The Sheba ARC Center (Accelerate, Redesign, Collaborate) brings together key players in digital medicine - physicians, researchers, start-ups, investors, and top-tier medical centers with the goal of redesigning healthcare.

“Our innovation room at ARC physically connects us to the main players there and encourages us all to collaborate”, said Clive Kaye, Managing Director for Janssen Israel.

"Our strategy - as is Sheba's - is to lead by innovation. We're a very patient-centric company with the goal to 'go beyond the pill' - adding value to our customers and maximizing treatment results”.

Janssen is partnering with Sheba in three key areas:

1. Supporting promising Israeli digital medicare solutions

2. Getting valuable insights into the patient's journey, using synthetic data

3. Being on-site at ARC to interact with the main ecosystem players

“Our partnership with Sheba consists in finding technological solutions, looking at the therapeutic areas where we wish to focus, plus working with researchers and technology partners-usually start-ups”, said Clive.

He adds: “We currently focus on some digital health projects including areas such as Psychiatry, Gastroenterology and Oncology”.

Janssen Conducts research using synthetic data provided by MDClone. Performing research while using such data makes it easier and simpler to locate any event along a patient's journey without having to worry about patients' privacy issues.

Professor Eyal Zimlichman, the Chief Medical Officer as well as the Chief Innovation Officer at Sheba, added: “Janssen was the first industry partner who we signed. We learned very quickly that they share our audacity about where we want to be."

READ THE FULL SHEBA ARC DIGITAL REPORT HERE

Share

Featured Articles

Executive Q&A with Shuki Licht, SVP & CIO, Finastra

As SVP and Chief Innovation Officer Shuki Licht discusses life at Finastra, a provider of financial software applications, open-platform and marketplaces

Profits continue to soar for Belfast-based IT firm Kainos

Kainos sales grew by 29% from £235m to £303m, as reported in the financial year ending in March 2022. Major clients include the UK government and the NHS

Executive Q&A with Ciaran Dynes, CPO of Matillion

Ciaran Dynes is the Chief Product Officer of cloud data warehouse startup, Matillion. He reveals how they have risen to unicorn status as a startup

Executive Q&A with Tom Homer, President, GTT

Enterprise IT

Trailblazer: Genevieve Bell - a leading mind in cybernetics

AI & Machine Learning

The store is dead, long live the store

Digital Transformation